Dr. Mike Hart interviews board-certified urologist Dr. Alex Tatum about peptide access, compounding, and men's health. Tatum argues many peptides are naturally occurring and lacked FDA commercialization incentives, says the FDA's 2023 move banning 19 compounds from Category 1 was contested due to no produced adverse-safety evidence, and describes the patient impact and advocacy around a July PCAC meeting. He explains most peptide APIs and many compounded GLP-1 ingredients come from China, while pharma-grade GLP-1s have more U.S. production. The discussion covers retatrutide's potential biologic classification (40–amino acid rule) and pricing implications, MOTS-c as an adjunct for low energy on GLP-1s, skepticism about cardarine, growth hormone secretagogues and cancer fears, TRT dosing frequency, sleep apnea screening, HCG's roles, and penis enhancement via traction for length and hyaluronic acid filler for girth, emphasizing expectations and mental health.
Dr. Alex Tatem is a board-certified urologist focused on men's health, hormone optimization, male fertility, and sexual wellness. In this episode, he joins Dr. Mike Hart to discuss the changing landscape of peptide therapy, including FDA restrictions, compounding pharmacies, drug supply chains, and the growing debate around access to treatments such as BPC-157, MOTS-c, and retatrutide. He also breaks down practical considerations for men using testosterone replacement therapy, including HCG, fertility preservation, dosing frequency, estrogen-related side effects, and sleep apnea risk. Drawing from his experience treating a wide range of patients, he shares a harm-reduction approach to performance medicine and explains what men should understand before considering growth hormone peptides, GLP-1 medications, or penile enhancement procedures.
Dr. Alex Tatem Website
https://dralextatem.com/
Dr. Alex Tatem Instagram
https://www.instagram.com/dralextatem/
Huberman Lab — Peptides: The Science, Uses & Safety | Dr. Abud Bakri
https://www.hubermanlab.com/episode/peptides-the-science-uses-and-safety-abud-bakri
FDA Pharmacy Compounding Advisory Committee Meeting — July 23–24, 2026
https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
FDA Bulk Drug Substances Under Section 503A
https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
FDA Compounding Safety Risks
https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
Semaglutide / Ozempic
https://medlineplus.gov/druginfo/meds/a618008.html
Tirzepatide / Mounjaro
https://medlineplus.gov/druginfo/meds/a622044.html
Retatrutide Clinical Trial
https://clinicaltrials.gov/study/NCT05929066
Testosterone Cypionate
https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=testosterone%20cypionate
Human Chorionic Gonadotropin / HCG
https://pubmed.ncbi.nlm.nih.gov/?term=human+chorionic+gonadotropin
BPC-157
https://pubmed.ncbi.nlm.nih.gov/?term=BPC-157
KPV Peptide
https://pubmed.ncbi.nlm.nih.gov/?term=KPV+peptide
TB-500 / Thymosin Beta-4
https://pubmed.ncbi.nlm.nih.gov/?term=thymosin+beta-4
MOTS-c
https://pubmed.ncbi.nlm.nih.gov/?term=MOTS-c
CJC-1295
https://pubmed.ncbi.nlm.nih.gov/?term=CJC-1295
Ibutamoren / MK-677
https://pubmed.ncbi.nlm.nih.gov/?term=ibutamoren+MK-677
Cardarine / GW501516
https://pubmed.ncbi.nlm.nih.gov/?term=GW501516+cardarine
PhalloFILL at Urology of Indiana
https://menshealthin.com/services/phallofill/
Hyaluronic Acid Penile Girth Enhancement Overview
https://auanews.net/issues/articles/2024/august-extra-2024/office-and-surgical-technologies-the-evolving-landscape-of-penile-girth-enhancement
Show Notes
00:00 Welcome to the Hart2Heart Podcast
00:33 Are Peptides Threatening Pharma
01:17 Patent Law and FDA Categories
02:19 The 2023 Peptide Ban Fallout
03:59 Safety or Money Debate
06:09 China Supply Chain Exposed
11:33 RFK Jr Peptide Messaging
16:01 Retatrutide Biologic Fight
20:51 What Biologic Status Costs
25:27 MOTS-c as GLP-1 Booster
28:43 Growth Hormone Cancer Myth
32:18 Sleep Effects and Bryan Johnson
35:04 Microplastics and Saunas
36:48 Cardarine Cancer Risk
40:07 TRT and HCG Basics
45:08 HCG Dosing Nuance
49:06 Daily TRT Microdosing
52:03 Sleep Apnea on TRT
56:34 Penis Enhancement Options
01:02:54 Realistic Expectations
01:04:46 Wrap Up and Where to Follow
The Hart2Heart podcast is hosted by family physician Dr. Michael Hart, who is dedicated to cutting through the noise and uncovering the most effective strategies for optimizing health, longevity, and peak performance.
This podcast dives deep into evidence-based approaches to hormone balance, peptides, sleep optimization, nutrition, psychedelics, supplements, exercise protocols, leveraging sunlight, and de-prescribing pharmaceuticals — using medications only when absolutely necessary.
Beyond health science, we explore the intersection of public health and politics, exposing how policy decisions shape our health landscape and what actionable steps people can take to reclaim control over their well-being.
Guests range from out-of-the-box thinking physicians such as Dr. Casey Means (author of "Good Energy") and Dr. Roger Sehult (Medcram lectures) to public health experts such as Dr. Jay Bhattacharya (Director of the National Institutes of Health (NIH) and Dr. Marty Mckary
(Commissioner of the Food and Drug Administration (FDA) and high-profile names such as
Zuby and Mark Sisson (Primal Blueprint and Primal Kitchen).
If you're ready to take control of your health and performance, this podcast is for you.We cut through the jargon and deliver practical, no-BS advice that you can implement in your daily life, empowering you to make positive changes for your well-being.
Connect with Dr. Mike Hart
Instagram: @drmikehart
Twitter: @drmikehart
Facebook: @drmikehart
